[
  {
    "slug": "corcept-therapeutics-stock-price-target-cut-by-canaccord-on-fda-setback",
    "title": "Corcept Therapeutics stock price target cut by Canaccord on FDA setback",
    "description": null,
    "fullText": null,
    "readingTime": 0,
    "keywords": [],
    "qualityScore": 0,
    "link": "https://www.investing.com/news/analyst-ratings/corcept-therapeutics-stock-price-target-cut-by-canaccord-on-fda-setback-93CH-4427594",
    "thumbnail_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_108x81.jpg",
    "created_at": "2026-01-02T12:22:19.278Z",
    "topic": "finance"
  },
  {
    "slug": "guggenheim-reiterates-buy-rating-on-axsome-stock-amid-fda-priority-review",
    "title": "Guggenheim reiterates Buy rating on Axsome stock amid FDA priority review",
    "description": null,
    "fullText": null,
    "readingTime": 0,
    "keywords": [],
    "qualityScore": 0,
    "link": "https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-buy-rating-on-axsome-stock-amid-fda-priority-review-93CH-4427600",
    "thumbnail_url": "https://i-invdn-com.investing.com/news/news_pile_108x81.jpg",
    "created_at": "2026-01-02T12:22:19.188Z",
    "topic": "finance"
  },
  {
    "slug": "fda-grants-priority-review-for-axsomes-alzheimers-agitation-drug",
    "title": "FDA grants priority review for Axsome’s Alzheimer’s agitation drug",
    "description": null,
    "fullText": null,
    "readingTime": 0,
    "keywords": [],
    "qualityScore": 0,
    "link": "https://www.investing.com/news/company-news/fda-grants-priority-review-for-axsomes-alzheimers-agitation-drug-93CH-4426423",
    "thumbnail_url": "https://i-invdn-com.investing.com/news/world_news_2_108x81.jpg",
    "created_at": "2025-12-31T12:22:36.959Z",
    "topic": "finance"
  },
  {
    "slug": "fda-supports-axsomes-nda-submission-for-narcolepsy-drug-axs12",
    "title": "FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12",
    "description": null,
    "fullText": null,
    "readingTime": 0,
    "keywords": [],
    "qualityScore": 0,
    "link": "https://www.investing.com/news/company-news/fda-supports-axsomes-nda-submission-for-narcolepsy-drug-axs12-93CH-4426413",
    "thumbnail_url": "https://i-invdn-com.investing.com/news/world_news_2_108x81.jpg",
    "created_at": "2025-12-31T12:22:36.944Z",
    "topic": "finance"
  },
  {
    "slug": "us-fda-approves-vanda-pharmaceuticals-motion-sickness-drug",
    "title": "US FDA approves Vanda Pharmaceuticals’ motion sickness drug",
    "description": null,
    "fullText": null,
    "readingTime": 0,
    "keywords": [],
    "qualityScore": 0,
    "link": "https://www.investing.com/news/stock-market-news/us-fda-approves-vanda-pharmaceuticals-motion-sickness-drug-4426090",
    "thumbnail_url": "https://i-invdn-com.investing.com/trkd-images/LYNXMPELBT0X7_L.jpg",
    "created_at": "2025-12-31T00:57:57.262Z",
    "topic": "finance"
  }
]